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Background: Cancer cell lines have a prominent role in the initial stages of drug discovery, facilitating
high-throughput screening of potential drugs. However, their clinical relevance remains controversial.
Findings: We assess whether drug sensitivity in cancer cell lines is able to discriminate tissue specificity.
We find that cancer-specific drugs do not show higher efficacies in cell lines representing the respective tissues. Even
when considering distinct cancer subtypes and targeted therapies, most drugs are evenly effective/ineffective
throughout all cell lines.
Conclusions: To get the most out of cell line panels, it will be necessary to look into their molecular characteristics,
and integrate them into systems biology frameworks.
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Human cancer cell lines are widely used in vitro models
for studying cancer and its biology [1]. Apart from being
valuable tools for identifying biomarkers and genetic var-
iants that impact drug sensitivities [2,3], cancer cell lines
play a pivotal role in the early stages of drug discovery,
facilitating the screening of hundreds of potential drugs
and their combinations before translating the outcomes
into in vivo models and expensive clinical trials [4,5].
However, despite their fundamental role in biomedical
research, the clinical relevance of cell lines remains highly
controversial [6,7]. Apart from known technical and bio-
logical limitations, like contamination, missing tumor
microenvironment, or lack of drug distribution and me-
tabolism, the main concern is whether cancer cell lines
are true representatives of primary tumors [8]. Prolonged
culturing of immortalized cell lines may induce extensive
modifications in their molecular characteristics, like sec-
ondary genomic changes [7,9], and it remains unclear how
closely they still resemble the original tissue after under-
going a certain number of passages. To complement the* Correspondence: patrick.aloy@irbbarcelona.org
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unless otherwise stated.ongoing debate from a pharmacological perspective, we
analyzed the predictive power of cancer cell lines for eluci-
dating cancer-specific drug responses. Considering the
widely used NCI-60 panel [5], we assessed whether drugs
for a particular cancer type display a higher efficacy in cell
lines supposedly representing the respective cancer tissue.
We focused on three cancer types, namely, breast, colo-
rectal and prostate cancer, represented by five, seven and
two cell lines, respectively, in the NCI-60. We analyzed all
the 75 compounds, approved or experimental, associated
with the treatment of these cancers that have also been
tested in the NCI-60 (Additional file 1: Table S1 and
Additional file 2: Table S2). We examined the sensitiv-
ity of each drug by considering its GI50 across the
complete NCI-60 panel, derived from nine cancer tis-
sues. The GI50, similar to IC50 and EC50, indicates the
concentration required to inhibit cell proliferation by
50%, relative to untreated samples [5]. Note that we
studied the activity of final drugs instead of the prelim-
inary hit compounds expecting that the former remain
active after preclinical optimization. Figure 1A shows
the sensitivity of the corresponding cancer cell lines
towards cancer-specific agents (highlighted in red) in
comparison to the sensitivity measured in cell lines repre-
senting other cancer tissues. Surprisingly, cancer-specific
drugs do not show a significantly higher activity in cell
lines representing the respective tissue (Wilcoxon testThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Tissue specificity displayed by caner-specific drugs. (A) Sensitivity of cancer-specific drugs intended for breast cancer (41), colorectal
cancer (24) and prostate cancer (38) across the NCI-60 panel covering 59 cancer cell lines derived from nine cancer tissues. The GI50 represents
the negative log of the concentration that is required to inhibit the growth of a cell line by 50%. Each box represents the distribution of drug
activities in a given cell line. Cell lines are organized in tissue slots. In red, we highlight the cell lines representing the intended tissue of the drugs.
(B) Breast cancer subtype-specific analysis. Stratification of targeted agents according to the different breast cancer subtypes. Note that agents
might be used for more than one subtype. (C) Sensitivity of HR-positive and triple negative breast cancer drugs with respect to subtype-specific
breast cancer cell lines. Red indicates high drug activity while green indicates inactivity for a given cell line.
Jaeger et al. Molecular Cancer  (2015) 14:40 Page 2 of 4with Bonferroni correction for multiple testing; see
Additional file 1). The same trend can be observed
when focusing only on approved drugs or more specific
targeted agents, and after normalizing drug sensitivity
values across cell lines. To avoid biases caused by drugswith multiple therapeutic indications, we also analyzed
more restrictive sets containing compounds exclusively
associated with breast, colorectal or prostate cancers,
obtaining equivalent outcomes (Additional file 1: Figures
S1, S2 and S3). Overall, our results indicate that a simple
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does not reflect the eventual complexity in the clinics.
Given the intrinsic heterogeneity of most cancers [10],
no individual cell line is likely to be a general representa-
tive for the distinct cancers derived from one tissue [11].
Hence, we do not expect a tissue-specific drug to perform
equally well across the corresponding cell lines. Breast
cancer, for instance, is a heterogeneous disease with at
least four recognized subtypes that require a specific treat-
ment [12,13]. Most researchers select particular cell lines
based on receptor status, common genetic mutations, mo-
lecular signatures, tumor type, as well as technical or
methodological limitations for their experiments [14].
Thus, mimicking this common approach, we considered
the presence or absence of biomarkers that define the
distinct breast cancer subtypes. Next we examined
whether subtype-specific responses are reflected in cell
lines representing distinct subtypes. The NCI-60 covers
two subtypes, the triple-negative breast cancer (BT-549,
HS-578 T and MDA-MB-231) and the HR-positive breast
cancer subtype (MCF7 and T-47D). Neither the HER2-
overexpressing nor the normal-like subtypes are included
in the panel. Among the 25 targeted breast-cancer agents,
18 are indicated for HR-positive patients, 6 for triple-
negative and 4 for HER2-overexpressing breast cancer
(Figure 1B and Additional file 1: Table S3). According to
this stratification, we assessed the sensitivity of the
subtype-specific drugs in the corresponding cell lines.
Figure 1C shows that the majority of drugs is equally
active or inactive independent of the breast cancer sub-
type. Figitumumab, vandetanib, and gefitinib (I), for
example, are evenly effective in HR-positive and triple-
negative cell lines, while aromatase inhibitors like letrozole,
anastrozole and aminoglutethimide are basically inactive
and would not have been discovered through screening cell
lines from this panel. Only four out of 18 HR-positive
drugs, i.e., PD-332991, raloxifene, tamoxifen (I), and fulves-
trant, exhibit a higher specificity in at least one of the
HR-positive cell lines. Conversely, midostaurin, a targeted
drug against HR-positive tumors, only shows activity in
triple-negative cell lines. As the NCI-60 only involves five
breast cancer cell lines, which only partially reflect the
distinct subtypes, we performed the same analysis on the
more comprehensive Cancer Cell Line Encyclopedia
(CCLE) [15]. Considering 30 breast cancer cell lines and 14
targeted agents, both stratified into subtypes, we still ob-
serve a largely varying compound sensitivity rather than
subtype-specific responses in the corresponding cell lines
(Additional file 1: Figure S4). Thus, even when accounting
for subtype-specific differences in the NCI-60, or consider-
ing a much larger cell line panel with a broader representa-
tion of breast cancer subtypes [15] (see Additional file 1:
Figure S4), the previously observed tendencies regarding
tissue specificity still hold.Similarly, we investigated whether intended drug targets
are expressed in the corresponding cell lines and, if so,
whether the drug is active in this cell line, exploiting pro-
teomics data of NCI-60 [16]. Again, we could not correlate
target expression with drug sensitivity (Additional file 1:
Figure S5). One of the few exceptions is presented by the
set of EGFR modulators, Gefitinib and Erlotinib, to which
cell lines are indeed more sensitive when EGFR is
expressed. Yet, in the majority of instances drug activity
does not depend on the presence or absence of the
intended targets, which indicates that several factors, be-
yond target expression, determine drug sensitivity.
Although alternative models for drug screening and de-
velopment are generated [9], cancer cell lines have been
and will be an essential component of cancer research and
drug discovery [17]. However, as we observed, relying on
assays performed in a few selected cell lines may result in
incorrect or misleading conclusion, and thus is unlikely to
predict clinical outcomes. Cell line panels, on the other
hand, may embrace the underlying complexity and vari-
ability of cancer. Yet, to fully exploit their invaluable poten-
tial, we have to move beyond ‘one marker, one cell line’
studies and incorporate the large amount of molecular
(‘omics’) profiles into robust systems biology frameworks
[15,16,18-20]. We believe that identifying and combining
the key features that each cell line is able to reproduce, be-
yond tissue and subtype specificity, will bring screening
panels at the forefront of a more successful drug discovery.Additional files
Additional file 1: Table S1. Summary of cancer-specific drugs
assembled and mapped per cancer type. BC – breast cancer,
CRC – colorectal cancer, PC – prostate cancer. Note that some drugs could
be mapped onto several NCI-60 tested compounds. Table S3. Classification
of targeted breast cancer agents tested in the NCI-60 into distinct subtypes
according to the FDA Orange Book, the NCI, ClinicalTrials.gov and the
literature. B – basal/triple negative, HR – hormone receptor positive,
H2 – HER2-overexpressing cancer, U – subtype indication unknown.
Table S4. Classification of targeted breast cancer agents, screened in
the CCLE, into distinct subtypes according to the FDA Orange Book,
the NCI, ClinicalTrials.gov and the literature. B – basal/triple negative,
HR – hormone receptor positive, H2 – HER2-overexpressing cancer,
U – subtype indication unknown. Figure S1. Sensitivity of the breast
cancer-specific drug sets considering (A) approved and (B) targeted
drugs, (C) normalized drug sensitivities, as well as (D) Unique and (E)
Unique* drugs. Figure S2. Sensitivity of the colorectal cancer-specific
drug sets considering (A) approved and (B) targeted drugs, (C) normalized
drug sensitivities, as well as (D) Unique and (E) Unique* drugs. Figure S3.
Sensitivity of the prostate cancer-specific drug sets considering (A) approved
and (B) targeted drugs, (C) normalized drug sensitivities, as well as the (D)
Unique and (E) Unique* sets. Figure S4. Sensitivity of drugs indicated for
hormone receptor positive, triple negative and HER2-overexpressing breast
cancer within 30 breast cancer cell lines representing the different subtypes.
Sensitivity is indicated in terms of the IC50. Red cells indicate high activity
while green cells indicate inactivity. Figure S5. Contingency tables grouping
target expression and discretized drug sensitivity of cell lines. Repeated
instances, such as EPHA2 – Dasatinib, correspond to different NCI-60
compounds, i.e., different formulation of the same drug.
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